This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Leerink Partners analyst Michael Cherny upgraded the rating for CVS Health Corporation CVS from Market Perform to Outperform and raised the price target from $55 to $75. CVS Health shares closed at $63.22 on Wednesday. See how other analysts view this stock.
Barclays analyst Duffy Fischer upgraded DuPont de Nemours, Inc. DD from Underweight to Equal-Weight and boosted the price target from $85 to $89. DuPont shares closed at $81.76 on Wednesday. See how other analysts view this stock.
Wells Fargo analyst Mohit Bansal upgraded the rating for Jazz Pharmaceuticals plc JAZZ from Equal-Weight to Overweight and raised the price target from $130 to $170. Jazz Pharmaceuticals shares closed at $135.44 on Wednesday. See how other analysts view this stock.
UBS analyst Matthew Weston upgraded AstraZeneca PLC AZN from Neutral to Buy. AstraZeneca shares closed at $74.43 on Wednesday. See how other analysts view this stock.
Morgan Stanley analyst Jeffrey Hung upgraded the rating for Cytokinetics, Incorporated CYTK from Equal-Weight to Overweight but lowered the price target from $70 to $67. Cytokinetics shares closed at $42.18 on Wednesday. See how other analysts view this stock.